Other Information .
−Removed: 10.1 †
−Removed: Amendment No.
−Removed: 3, dated as of October 14, 2020, to Executive
−Removed: Compensation Agreement between Gerald W.
−Removed: Crabtree and the Company
−Removed: Incorporated by reference from the Company’s Current
−Removed: Report on Form 8-K filed with the SEC on October 16, 2020.
+Added: Conformed version of the Company’s Articles of Incorporation, as amended by that Certificate of
+Added: Amendment previously filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K on November 8, 2019.
+Added: Incorporated by reference to the designated exhibit of the Company’s
+Added: Current Report on Form 10-Q filed on March 13, 2020.
+Added: Corporate Bylaws, as amended by that Amendment No.
+Added: 1 and Amendment No.
+Added: Filed herewith
Principal Executive Officer Certification required by Rules 13a-14 and 15d-14 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
8 unchanged sentences
Filed herewith
−Removed: Interactive Data Files for the Company’s Form 10-Q for the period ended October 31, 2020
+Added: Interactive Data Files for the Company’s Form 10-Q for the period ended January 31, 2021
Submitted herewith.
−Removed: Indicates a management contract or any compensatory
−Removed: plan, contract or arrangement.
Pursuant to the requirements of the Securities
2 unchanged sentences
PharmaCyte Biotech, Inc.
−Removed: December 11, 2020
+Added: March 12, 2021
/s/ Kenneth L.
1 unchanged sentence
(Duly Authorized Officer and Principal Executive Officer)
−Removed: December 11, 2020
+Added: March 12, 2021
/s/ Carlos A.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.